Title: Conditions for the achievement of pharmaceutical innovation for sustainable development: lessons from India

Authors: Dinesh Abrol

Addresses: National Institute of Science, Technology and Development Studies, Pusa Gate, K.S. Krishnan Marg, New Delhi 110 012, India

Abstract: This paper shows the post-TRIPS experience to be contradicting the overstated claim that ||the adverse effect of TRIPS Agreement on prices of patented medicines would be adequately compensated by the benefits of technology transfer and domestic R&D||. It argues that policymakers cannot continue to formulate their strategic interventions with an understanding that ||strong IPRs are going to help define the pharmaceutical knowledge markets to be competitive and favourable for the development of people oriented innovations||. Strategic interventions of the government should make the pharmaceutical sector to work for the benefit of therapies needed by the people of India and LDCs.

Keywords: pharmaceutical industry; TRIPS; outsourcing; technology transfer; R&D; research and development; public health; innovation; sustainable development; developing countries; government intervention; Agreement on Trade-Related Aspects of Intellectual Property Rights.

DOI: 10.1504/WRSTSD.2006.011113

World Review of Science, Technology and Sustainable Development, 2006 Vol.3 No.4, pp.344 - 361

Published online: 16 Oct 2006 *

Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article